arrow
C

Christian Rolfo

Harvard T.H. Chan School of Public Health
H指数:64
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Validation of histopathology-based deep learning algorithms for detection of actionable non-small cell lung cancer biomarkers

基于组织病理学的深度学习算法用于检测可操作的非小细胞肺癌生物标志物的验证

2026-01-200
OAAI
The influence of body mass index on tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

体重指数对转移性非小细胞肺癌患者肿瘤治疗电场疗法的影响:一项来自III期LUNAR研究的回顾性及模拟分析

2025-10-210
PRE
Molecular and clonal evolution of primary lesions vs. brain metastasis in EGFR-mutated NSCLC: a retrospective cohort study

EGFR突变型NSCLC中原发性病灶与脑转移灶的分子和克隆演化:一项回顾性队列研究

2025-09-300
PRE
BLOODPAC's collaborations with European Union liquid biopsy initiatives

Dickey, J.; Katrivanos, E.; Leiman, L.; Abukhdeir, A.; Cardone, A.; Saritas-Yildirim, B.; Galamba, C.; Jankiewicz, C.; Rolfo, C.; Bhandari, D.; 等. BLOODPAC与欧盟液体活检倡议的合作. J. Liq. Biopsy 2025, 10, 100321. [Google Scholar] [CrossRef]

2025-09-010
OAAI
Clinicogenomic and treatment outcomes in RET fusion-positive NSCLC: A multicenter study in Latin American Hispanic patients

临床基因组学和治疗结果在RET融合阳性NSCLC中:一项在拉丁美洲西班牙裔患者中的多中心研究

2025-09-010
OAAI
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

MEK1/2抑制剂比尼美替尼与MET抑制剂克唑替尼在RAS突变型晚期结直肠癌 (汞) 患者中的Ia/b期研究

2025-04-100
OAAI
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors

揭示循环肿瘤细胞的影响: 实体瘤的二十年发现和临床进展

2024-11-010
PRE
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

临床干预对肺癌患者SARS-CoV-2免疫的时间依赖性影响

2024-06-261
OAAI
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial (vol 42, pg 145, 2024)

CXCR2拮抗剂navarixin联合pembrolizumab治疗晚期实体瘤: 一项2期随机试验 (第42卷,145页,2024)

2024-05-200
OAAI